A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar
NCT04422171
·
clinicaltrials.gov ↗
UNKNOWN
Status
400
Enrollment
OTHER
Sponsor class
Conditions
IBD Patients, Originator Treatment, Biosimilar, Switch Back
Sponsor
University Hospital, Grenoble